About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
ETC-1002
- Company
- Esperion Therapeutics, Inc.
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- None currently listed
Efficacy results: Not yet reported
No recruiting studies currently listed
See all studies for this drugData source: ClinicalTrials.gov · trial data as of Sep 11, 2026
Trial details
-
Completed NCT NCT01105598
A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia
Not yet reported Esperion Therapeutics, Inc. 53 participants Est. completion 2010-10-02 1 site Stand-aloneOther conditions: Mild DyslipidemiaView official trial listing → -
Completed NCT NCT01262638
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
Not yet reported Esperion Therapeutics, Inc. 177 participants Est. completion 2011-08-23 11 sites Stand-aloneOther conditions: DyslipidemiaView official trial listing → -
Completed NCT NCT01485146
A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects
Not yet reported Esperion Therapeutics, Inc. 24 participants Est. completion 2012-01-25 1 site Stand-aloneOther conditions: Safety Evaluation of Escalating DosesView official trial listing → -
Completed NCT NCT01607294
A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes
Not yet reported Esperion Therapeutics, Inc. 60 participants Est. completion 2012-10 1 site Stand-aloneType 2 diabetes Other conditions: HyperlipidemiaView official trial listing → -
Completed NCT NCT01751984
A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance
Not yet reported Esperion Therapeutics, Inc. 56 participants Est. completion 2013-05-01 5 sites Stand-aloneOther conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT01779453
A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia
Not yet reported Esperion Therapeutics, Inc. 58 participants Est. completion 2013-08 3 sites Stand-aloneOther conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT01941836
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
Not yet reported Esperion Therapeutics, Inc. 349 participants Est. completion 2014-11 68 sites Stand-aloneOther conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT02044627
Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002
Not yet reported Esperion Therapeutics, Inc. 6 participants Est. completion 2014-01 1 site Stand-aloneOther conditions: HyperlipidemiaView official trial listing → -
Completed NCT NCT02072161
Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy
Not yet reported Esperion Therapeutics, Inc. 133 participants Est. completion 2015-01 40 sites Stand-aloneOther conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT02178098
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
Not yet reported Esperion Therapeutics, Inc. 143 participants Est. completion 2015-05-22 43 sites Stand-aloneOther conditions: Hypercholesterolemia, HypertensionView official trial listing → -
Completed NCT NCT02659397
A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg
Not yet reported Esperion Therapeutics, Inc. 68 participants Est. completion 2016-07 19 sites Stand-aloneOther conditions: HyperlipidemiaView official trial listing → -
Completed NCT NCT02666664
Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
Not yet reported Esperion Therapeutics, Inc. 2230 participants Est. completion 2018-03-28 104 sites Stand-aloneCardiovascular disease Other conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT02988115
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
Not yet reported Esperion Therapeutics, Inc. 345 participants Est. completion 2018-03-16 67 sitesCardiovascular disease Other conditions: Hypercholesterolemia, Statin Adverse ReactionView official trial listing → -
Completed NCT NCT02991118
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
Not yet reported Esperion Therapeutics, Inc. 779 participants Est. completion 2018-08-22 2 sitesCardiovascular disease Other conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT02993406
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
Not yet reported Esperion Therapeutics, Inc. 13970 participants Est. completion 2022-11-07 1319 sitesCardiovascular disease Other conditions: Statin Adverse ReactionView official trial listing → -
Completed NCT NCT03001076
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
Not yet reported Esperion Therapeutics, Inc. 269 participants Est. completion 2018-02-12 1 siteOther conditions: Hypercholesterolemia, Atherosclerosis, Statin Adverse ReactionView official trial listing → -
Completed NCT NCT03051100
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
Not yet reported Esperion Therapeutics, Inc. 63 participants Est. completion 2017-07-05 11 sitesOther conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT03067441
Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
Not yet reported Esperion Therapeutics, Inc. 1462 participants Est. completion 2019-11-05 3 sitesCardiovascular disease Other conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT03193047
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy
Not yet reported Esperion Therapeutics, Inc. 59 participants Est. completion 2018-02-19 1 siteOther conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT03337308
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
Not yet reported Esperion Therapeutics, Inc. 382 participants Est. completion 2018-07-18 5 sitesOther conditions: HyperlipidemiasView official trial listing → -
Completed NCT NCT04784442
A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia
Not yet reported Otsuka Pharmaceutical Co., Ltd. 188 participants Est. completion 2022-05-17 1 site Stand-aloneOther conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT05683340
A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
Not yet reported Otsuka Pharmaceutical Co., Ltd. 96 participants Est. completion 2024-03-12 1 site Stand-aloneOther conditions: Hyper-low-density Lipoprotein (LDL) CholesterolemiaView official trial listing → -
Completed NCT NCT05687071
A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
Not yet reported Otsuka Pharmaceutical Co., Ltd. 130 participants Est. completion 2024-11-02 1 site Stand-aloneOther conditions: Hyper-low-density Lipoprotein (LDL) CholesterolemiaView official trial listing → -
Completed NCT NCT05694260
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Not yet reported Esperion Therapeutics, Inc. 31 participants Est. completion 2025-06-04 24 sitesOther conditions: HypercholesterolemiaView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.